AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies
25 sept. 2024 08h00 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AskBio and Belief BioMed will work together to advance potential gene...
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
11 juil. 2024 08h00 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (formerly known as AAV2-GDNF) is being studied for the treatment of...
AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
25 juin 2024 08h00 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic...
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024
02 mai 2024 08h00 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG,...
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
18 avr. 2024 08h00 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is being studied for the treatment of adults with non-ischemic...
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
16 avr. 2024 08h03 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
AskBio Names Mansuo Shannon Chief Scientific Officer
09 avr. 2024 08h00 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyCo-Founder and former Chief...
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
13 févr. 2024 08h10 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is an investigational gene therapy for the treatment of adults with...
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
05 janv. 2024 08h11 HE
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer...
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
28 janv. 2021 09h20 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company and wholly owned...